Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Manufacturing allogeneic CAR-NKs for the treatment of multiple myeloma

Joaquin Martinez-Lopez • 25 Aug 2022
IMS 2022
Multiple Myeloma CAR-NK NK-Cell Therapy

Joaquin Martinez-Lopez, MD, PhD, Complutense University of Madrid, Madrid, Spain, briefly explains how to manufacture allogeneic CAR-NKs for the treatment of multiple myeloma, commenting on cell source and molecules that can be used to enhance the survival of NK cells. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Joaquin Martinez-Lopez

1:26
Laboratory techniques used for immune evaluation in multiple myeloma
Joaquin Martinez-Lopez • 25 Aug 2022
1:19
Infectious toxicities in patients with multiple myeloma treated with bispecific antibodies
Joaquin Martinez-Lopez • 25 Aug 2022
5:53
COVID-19 in myeloma: what have we learnt?
Joaquin Martinez-Lopez • 10 Sep 2021
1:10
Real-life analysis of myeloma patient survival in a third-level hospital
Joaquin Martinez-Lopez • 10 Sep 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals